MX2021004404A - Metodo para purificar anticuerpo que tiene bajo punto isoelectrico. - Google Patents

Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.

Info

Publication number
MX2021004404A
MX2021004404A MX2021004404A MX2021004404A MX2021004404A MX 2021004404 A MX2021004404 A MX 2021004404A MX 2021004404 A MX2021004404 A MX 2021004404A MX 2021004404 A MX2021004404 A MX 2021004404A MX 2021004404 A MX2021004404 A MX 2021004404A
Authority
MX
Mexico
Prior art keywords
antibody
low
isoelectric point
purifying antibody
low isoelectric
Prior art date
Application number
MX2021004404A
Other languages
English (en)
Inventor
Yasufumi Ueda
Shohei Kobayashi
Satoko Yanagita
Takuo Kawase
Masahiro Fukunaga
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021004404A publication Critical patent/MX2021004404A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a la agregación adicional de anticuerpo de bajo pI que puede ser suprimida removiendo agregados de anticuerpo formados después de un cierto periodo de tiempo después de la purificación de columna de Proteína A, tratamiento acídico, y neutralización. Además, los presentes inventores encontraron que la remoción eficiente de impurezas para un anticuerpo de bajo pI puede ser realizada usando una resina de intercambio aniónico en el modo Unión/Eluato y después una resina de cromatografía de interacción hidrofóbica o cromatografía multimodal, comparada con los métodos convencionales.
MX2021004404A 2013-12-27 2016-06-24 Metodo para purificar anticuerpo que tiene bajo punto isoelectrico. MX2021004404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013271613 2013-12-27

Publications (1)

Publication Number Publication Date
MX2021004404A true MX2021004404A (es) 2021-06-15

Family

ID=53479003

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008498A MX2016008498A (es) 2013-12-27 2014-12-26 Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
MX2021004404A MX2021004404A (es) 2013-12-27 2016-06-24 Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016008498A MX2016008498A (es) 2013-12-27 2014-12-26 Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.

Country Status (16)

Country Link
US (1) US10654933B2 (es)
EP (1) EP3088411A4 (es)
JP (1) JP6722455B2 (es)
KR (1) KR102344170B1 (es)
CN (1) CN106029682B (es)
AU (1) AU2014370873B2 (es)
BR (1) BR112016014824A2 (es)
CA (2) CA3233584A1 (es)
IL (3) IL296754A (es)
MX (2) MX2016008498A (es)
MY (1) MY181081A (es)
NZ (1) NZ722057A (es)
RU (1) RU2714967C2 (es)
SG (1) SG11201605256YA (es)
TW (2) TWI715524B (es)
WO (1) WO2015099165A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6823596B2 (ja) 2015-07-31 2021-02-03 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
RS63533B1 (sr) 2016-12-23 2022-09-30 Serum Institute Of India Pvt Ltd Postupci za povećanje produktivnosti antitela u kulturi sisarskih ćelija i smanjenje agregacije tokom nishodne obrade, postupci formulacije i rezultujuće stabilne formulacije antitela
AU2018218557B9 (en) * 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
US11945839B2 (en) * 2017-12-22 2024-04-02 Hoffmann-La Roche Inc. Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4891312A (en) * 1986-08-13 1990-01-02 Monsanto Company Monoclonal antibody specific for human colon fibroblast-derived t-PA
JPS63149900A (ja) 1986-12-15 1988-06-22 Toshiba Corp 半導体メモリ
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
EP0804487A2 (en) * 1993-04-09 1997-11-05 Chiron Corporation Bispecific antigen-binding molecules
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CN100335501C (zh) 1996-09-26 2007-09-05 中外制药株式会社 抗人副甲状腺激素相关蛋白的抗体
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
PL343322A1 (en) 1998-04-03 2001-08-13 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
TWI241345B (en) 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
WO2002033072A1 (en) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Degraded tpo agonist antibody
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
ES2418830T3 (es) 2003-10-27 2013-08-16 Wyeth Llc Retirada de agregados de alto peso molecular usando cromatografía de hidroxiapatita
US20080058507A1 (en) 2004-02-11 2008-03-06 Hui Liu Method For The Removal Of Aggregate Proteins From Recombinant Samples Using Ion Exchange Chromatography
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
KR101588276B1 (ko) * 2007-08-10 2016-01-26 센토코 오르토 바이오테크 인코포레이티드 질환 표시자로서의 면역글로불린 절단 단편, 및 그의 검출 및 결합을 위한 조성물
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
DK2236604T3 (en) 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
AU2009270726B2 (en) 2008-07-18 2015-07-09 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
JP2010041761A (ja) * 2008-07-31 2010-02-18 Thk Co Ltd リニアモータ
AU2009307737B2 (en) * 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
TWI440470B (zh) * 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd 含改良抗體分子之醫藥配方
JP5721204B2 (ja) * 2009-04-09 2015-05-20 旭化成ケミカルズ株式会社 アニオン交換基が固定された多孔膜を用いた抗体モノマーの精製方法
MY171234A (en) * 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
US20130336972A1 (en) 2010-08-26 2013-12-19 Christian Klein Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
SG189872A1 (en) * 2010-10-11 2013-06-28 Abbvie Inc Processes for purification of proteins
JP5828902B2 (ja) * 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
EP2640742B1 (en) * 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
WO2012135912A1 (en) * 2011-04-05 2012-10-11 Resmed Limited Respiratory breathing apparatus
WO2013012022A1 (ja) * 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
KR20200008022A (ko) * 2011-12-22 2020-01-22 제넨테크, 인크. 이온 교환 막 크로마토그래피
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient

Also Published As

Publication number Publication date
AU2014370873A1 (en) 2016-07-14
US20160326253A1 (en) 2016-11-10
JPWO2015099165A1 (ja) 2017-03-23
MY181081A (en) 2020-12-17
TW201609790A (zh) 2016-03-16
IL296754A (en) 2022-11-01
SG11201605256YA (en) 2016-08-30
CA2935143A1 (en) 2015-07-02
CA3233584A1 (en) 2015-07-02
TWI787590B (zh) 2022-12-21
JP6722455B2 (ja) 2020-07-15
CA2935143C (en) 2024-05-07
CN106029682B (zh) 2021-04-13
AU2014370873B2 (en) 2020-06-11
RU2016130664A (ru) 2018-02-01
WO2015099165A1 (ja) 2015-07-02
CN106029682A (zh) 2016-10-12
MX2016008498A (es) 2016-10-07
EP3088411A1 (en) 2016-11-02
TW202026304A (zh) 2020-07-16
RU2016130664A3 (es) 2018-11-14
BR112016014824A2 (pt) 2017-09-19
EP3088411A4 (en) 2018-12-19
IL288023A (en) 2022-01-01
TWI715524B (zh) 2021-01-11
IL246367A0 (en) 2016-08-31
KR20160102283A (ko) 2016-08-29
RU2714967C2 (ru) 2020-02-21
US10654933B2 (en) 2020-05-19
NZ722057A (en) 2022-10-28
KR102344170B1 (ko) 2021-12-27

Similar Documents

Publication Publication Date Title
MX2021004404A (es) Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
PH12016500878B1 (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
PH12015501687A1 (en) Novel binding proteins from pcsk9
EA201492101A1 (ru) Антитела против fcrn
EA201790455A1 (ru) Привитый растительный организм и способ его получения
CU20170039A7 (es) Método de purificación del anticuerpo humanizado 9e4
EA201791424A1 (ru) Получение белка
WO2015195453A3 (en) Methods for increasing the capacity of flow-through processes
MX2018007781A (es) Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
BR112016005982A2 (pt) renderização de áudio de multicanal utilizando matrizes interpoladas
BR112016015718A2 (pt) Processo de purificação de aminoácidos aromáticos
BR112016001461A2 (pt) Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína
MX2018001536A (es) Metodo para la reduccion de proteinas de celulas hospederas en cromatografia de afinidad.
EP3048112A4 (en) Fc-BINDING PROTEIN, METHOD FOR PRODUCING SAID PROTEIN, AND ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHODS FOR PURIFYING AND IDENTIFYING ANTIBODY USING SAID ADSORBENT
PH12018501070A1 (en) Anti-pcsk9 antibody and use thereof
WO2015021423A3 (en) Purification of chimeric fviii molecules
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX2017000831A (es) Cuantificacion de tnfr2 : fc plegada erroneamente.
WO2016012938A3 (en) Improved process for preparation of amorphous linaclotide
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
WO2014122079A3 (en) Improved purification of proteins via a deglycosylation step
IN2013MU02726A (es)
EP3373954A4 (en) PROCESS FOR PREPARING AND CLEANING MATRIX-BINDING FUSION PROTEINS BY ION EXCHANGE CHROMATOGRAPHY
MX2018001687A (es) Metodos y sistemas para extraer proteina de acido oxalico reducido de especies acuaticas y composiciones de la misma.